Baxter to enhance renal therapy portfolio with Gambro acquisition
Baxter has entered into a definitive agreement to acquire privately-held Gambro, based in Lund, Sweden, for total consideration of SKr 26.5 billion (approximately US$4.0 billion). Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The acquisition will give Baxter a comprehensive dialysis product portfolio, complementing its existing home dialysis offerings.
Gambro's portfolio in the traditional chronic care segment consists of haemodynamic devices including advanced monitors, dialysers, bloodlines, cyclers and dialysis systems. The company's in-centre haemodialysis devices include the Artis and the AK 96 systems. In the acute care segment, which includes continuous renal replacement therapy and treatment for fluid overload, among others, Gambro offers the Prismaflex system used for the treatment of critically ill patients with acute kidney injury.
It is believed that the transaction will provide a number of long-term growth opportunities for Baxter worldwide. With a broad and complementary dialysis product portfolio, Baxter can accelerate product sales in established markets such as Europe, where Gambro has an extensive footprint. Baxter can also expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis business. In addition, Baxter will also build upon its pipeline of investigational home haemodialysis and automated peritoneal dialysis systems with the addition of Gambro's monitors, dialysers, devices and dialysis systems.